Amp Volatility Score
Catalyst Info & Data Links
TITLE: TG-1701 (BTK) in B-Cell Malignancies
ClinicalTrial.gov NCT03671590: Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2018: End of Year 2018 SEC-10K
2020: Phase 1 Data European Hematology Association (EHA)
2020: TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro, and cooperates with the glycoengineered anti-CD20 mAb, ublituximab, in in vivo mantle cell lymphoma models (AACR)
115,000 Americans living with CLL
~20,000 newly-diagnosed patients each year
~20,000 previously treated patients seeking treatment each year
Source - (slide 11) Raymond James 2020 Human Health Innovation Conference
MECHANISM OF ACTION / RATIONALE
B-cell receptor (BCR) signaling is crucial for normal B-cell development and supports the survival and growth of malignant B-cells in patients with B-cell leukemias or lymphomas. Targeting BTK, an essential element of BCR signaling pathway which regulates the survival, activation, proliferation, and differentiation of B lymphocytes, has shown remarkable efficacy with an acceptable safety profile in B-cell malignancies.
Updated by HC
TGTX, TG-1701, B-Cell_Malignancies
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post